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Background: Bile acid induced apoptosis in hepatocytes can be antagonised by nuclear factor kB (NFkB)
dependent survival pathways. Sulfasalazine modulates NFkB in different cell types. We aimed to
determine the effects of sulfasalazine and its metabolites sulfapyridine and 5-aminosalicylic acid (5-ASA)
on bile acid induced apoptosis in hepatocytes.
Methods: Apoptosis was determined by caspase assays and immunoblotting, NFkB activation by
electrophoretic mobility shift assay and reporter gene assays, generation of reactive oxygen species (ROS)
fluorometrically, bile secretion gravimetrically, and bile acid uptake radiochemically and by gas
chromatography in HepG2-Ntcp cells and isolated perfused rat livers.
Results: Glycochenodeoxycholic acid (GCDCA 75 mmol/l) induced apoptosis was reduced by
sulfasalazine dose dependently (1–1000 mmol/l) in HepG2-Ntcp cells whereas its metabolites 5-ASA
and sulfapyridine had no effect. Sulfasalazine significantly reduced GCDCA induced activation of
caspases 9 and 3. In addition, sulfasalazine activated NFkB and decreased GCDCA induced generation
of ROS. Bile acid uptake was competitively inhibited by sulfasalazine. In perfused rat livers, GCDCA
(25 mmol/l) induced liver injury and extensive hepatocyte apoptosis were significantly reduced by
simultaneous administration of 100 mmol/l sulfasalazine: lactate dehydrogenase and glutamate-pyruvate
transaminase activities were reduced by 82% and 87%, respectively, and apoptotic hepatocytes were
observed only occasionally. GCDCA uptake was reduced by 45 (5)% when sulfasalazine was
coadministered. However, when 50% of GCDCA (12.5 mmol/l) was administered alone, marked
hepatocyte apoptosis and liver injury were again observed, questioning the impact of reduced GCDCA
uptake for the antiapoptotic effect of sulfasalazine.
Conclusion: Sulfasalazine is a potent inhibitor of GCDCA induced hepatocyte apoptosis in vitro and in the
intact liver.
C
holestasis is a common feature of many human liver
diseases. Elevated bile acid concentrations in hepato-
cytes, a hallmark of cholestasis, promote liver cell death
resulting in liver injury and liver cirrhosis.1 Toxic bile acids
induce hepatocellular apoptosis, thereby providing a cellular
mechanism for bile acid mediated liver injury.2–4 The glycine
and taurine conjugates of chenodeoxycholic acid (GCDCA,
TCDCA) are the predominant dihydroxy bile acids in
cholestatic patients and have been held responsible for
cholestasis associated liver injury.5 Glycochenodeoxycholic
acid (GCDCA) is thought to induce hepatocyte apoptosis by a
Fas death receptor dependent process that is independent of
Fas ligand6 but induces oligomerisation of Fas by increasing
cell surface trafficking of Fas.7 GCDCA induced generation of
reactive oxygen species followed by epidermal growth factor
receptor dependent tyrosine phosphorylation of Fas also
appears to be required for GCDCA induced Fas signalling.4
The transcription factor nuclear factor kB (NFkB) has been
shown to reduce hepatocyte apoptosis induced by toxic bile
acids,8 tumour necrosis factor a (TNF-a), and during liver
regeneration.9 Thus NFkB is an important factor of several
antiapoptotic signalling cascades in the liver.
Sulfasalazine was synthesised in 1942 to combine an
antibiotic, sulfapyridine (SPD), and an anti-inflammatory
agent, 5-aminosalicylic acid (5-ASA), for the treatment of
rheumatoid arthritis.10 Later, sulfasalazine was also used
successfully in the treatment of inflammatory bowel diseases.
Although this drug has been used for decades, its mechanism
of action remains a matter of debate. Numerous pharmaco-
logical and biochemical effects have been described, includ-
ing modulatory effects on leucocyte function.11 Recently, it
has been shown that sulfasalazine is a potent and specific
inhibitor of NFkB in human colon epithelial cells.12 In these
cells, sulfasalazine seems to be a direct inhibitor of IkB
kinases a and b by antagonising adenosine triphosphate
binding.13 However, it is not known if sulfasalazine or its
metabolites can also modify NFkB signalling in hepatocytes.
The overall objectives of this study were therefore to
examine the effects and potential mechanisms of sulfasala-
zine and its metabolites on GCDCA induced apoptosis in
hepatocytes. To address these objectives we used a human
hepatoma cell line stably transfected with the bile acid
transporter sodium taurocholate cotransporting polypeptide
(Ntcp) and isolated perfused rat livers.
MATERIAL AND METHODS
Reagents
ZVAD-FMK was from Promega (Madison, Wisconsin). 5-
(and-6)-Carboxy-29 79-dichloro-dihydrofluorescein diacetate
(carboxy-H2DCFDA) was from Molecular Probes (Eugene,
Oregon, USA).[3H]-Taurocholate was from Perkin Elmer
(Boston, Massachusetts, USA). Antibodies against cleaved
caspase 9 and cleaved caspase 3 were purchased from Cell
Signalling (Beverly, Massachusetts, USA). MG132 was from
Calbiochem (La Jolla, California, USA). GCDCA, sulfasalazine,
Abbreviations: 5-ASA, 5-aminosalicylic acid; DMSO, dimethyl
sulfoxide; EMSA, electrophoretic mobility shift assay; GCDCA,
glycochenodeoxycholic acid; GPT, glutamate-pyruvate transaminase;
LDH, lactate dehydrogenase; Ntcp, sodium taurocholate cotransporting
polypeptide; NFkB, nuclear factor kB; ROS, reactive oxygen species;
TCA, taurocholic acid; TNF-a, tumour necrosis factor a
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SPD, 5-ASA, dimethyl sulfoxide (DMSO), staurosporine, and all
other reagents were obtained from Sigma Chemical (St Louis,
Missouri, USA).
Cell culture
HepG2-Ntcp cells14 were grown at 37 C˚ under 5% CO2 in
MEM (pH 7.4) containing 10% fetal bovine serum, 1% non-
essential amino acids, 2 mmol/l l-glutamine, 1 mmol/l
sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomy-
cin, and 0.25 mg/ml amphotericin B.
[3H]Taurocholic acid uptake
Confluent HepG2-Ntcp cells were washed with a buffer
containing 100 mmol/l NaCl, 2 mmol/l KCl, 1 mmol/l CaCl2,
1 mmol/l MgCl2, 5.5 mmol/l d-glucose, and 10 mmol/l N-[2-
hydroxyethyl]piperazine-N9-[2-ethane sulfonic acid]
(pH 7.5, 37 C˚). After incubation in NaCl medium containing
1 mCi/ml [3H]taurocholic acid (TCA) and 10 mmol/l unla-
belled TCA at 37 C˚ for 20 minutes, cells were washed with an
ice cold NaCl medium containing 1 mmol/l unlabelled TCA
and lysed with 0.5 ml Triton X-100 (1%, v/v). Aliquots of
400 ml were dissolved in 10 ml of scintillation cocktail
(Ultima Gold Canberra Packard, Frankfurt/Main,
Germany). Radioactivity was quantified using a liquid
scintillation analyser (Packard Instrument Co., Frankfurt,
Germany).
Caspase assays
Caspase 3/7, and caspase 9 activation were determined in
subconfluent HepG2-Ntcp cells treated with GCDCA in the
absence or presence of sulfasalazine or the pancaspase
inhibitor ZVAD-FMK at the indicated concentrations and
time intervals. Commercially available caspase assay kits
from Promega were performed according to the recommen-
dations of the manufacturer.
Plasmids and transfection
Luciferase reporter plasmids p105 (cona-luc) and p106 (kB-
cona-luc) for NFkB reporter gene assays have been previously
described.8 The TK-Renilla-CMV plasmid was purchased from
Promega and used to normalise for transfection efficiency in
luciferase assays. HepG2-Ntcp cells at a confluence of
approximately 50% were transiently transfected using
FuGENE (Roche, Mannheim, Germany) and used 48 hours
after transfection.
Electrophoretic mobility shift assay (EMSA)
HepG2-Ntcp cells were stimulated with diluent or sulfasala-
zine at different concentrations. Nuclear proteins (6 mg) and
non-specific competitor poly(dIdC) (3 mg) were incubated in
binding buffer (100 mM HEPES, 300 mM KCl, 20% Ficoll,
0.05% NP-40, 0.5 mg/ml bovine serum albumin) with
3.5 pmol of double stranded DNA oligonucleotide containing
a NFkB consensus binding sequence (59-AGT TGA GGG GAC
TTT CCC AGG C-39) that was labelled with [c-32P]-ATP using
T4 polynucleotide kinase (Promega). Protein-DNA complexes
were separated from the unbound DNA probe by electro-
phoresis through 5% native polyacrylamide gels.
Luciferase reporter gene assay
HepG2-Ntcp cells were cotransfected with 0.2 mg of TK-
Renilla-CMV and 1.5 mg of either p105 or p106. Forty eight
hours later, cells were cultured in serum free MEM for 18–
24 hours and then stimulated with bile acids and/or
sulfasalazine for one hour. Both firefly and Renilla luciferase
activities were quantitated using dual reporter gene assays
from Promega, according to the manufacturer’s instructions
using a TD 20/20-Luminometer (Software Turner Design
Version 2.0.1, Turner Designs Inc., California, USA).
Background luciferase expression, as determined in cells
transfected with p105, was subtracted from p106 values.
Measurement of reactive oxygen species (ROS)
Confluent HepG2-Ntcp cells were incubated with carboxy-
H2DCFDA (4 mmol/l) for four hours at 37 C˚, washed three
times, incubated with GCDCA in the absence or presence of
sulfasalazine at the indicated concentrations for two hours at
37 C˚, and quantitated in a CytoFluor 4000 reader (Perseptive
Biosystems, Weiterstadt, Germany) using an excitation
wavelength of 485 nm and an emission wavelength of
530 nm.
Immunoblot analysis
Subconfluent cells were treated with staurosporine (5 mmol/
l) or GCDCA (75 mmol/l) in the absence or presence of
sulfasalazine, washed with phosphate buffered saline,
homogenised in ice cold lysis buffer (20 mM Tris-HCl pH 8,
150 mM NaCl, 2 mM EDTA, 1% Triton, 100 mM vanadate,
10 mM NaF), incubated for five minutes on ice, sonicated,
and centrifuged for five minutes at 14000 g and 4 C˚. The
supernatant was resolved by 12.5% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis, transferred to
Immobilon-P membranes (Millipore, Eschborn, Germany),
and probed against the appropriate primary antibody at a
dilution of 1:1000 in 5% milk/TBS-T overnight. Peroxidase
conjugated goat antirabbit IgG antibody (Santa Cruz
Biotechnologies, Santa Cruz, California, USA) was incubated
at a dilution of 1:4000. Membranes were stripped and
reprobed with anti-b-actin antibody (1:3500, Sigma) to
ensure equal loading.
Animals
Male Sprague-Dawley rats (229 (16) g) were obtained from
Charles River (Sulzfeld, Germany). They were subjected to a
12 hour day-night rhythm with unlimited access to food and
water.
Isolated rat liver perfusion
The technical procedure used has been described previously.15
In brief, livers were perfused in a non-recirculating fashion
with Krebs-Ringer bicarbonate solution at 37 C˚ at a constant
flow rate of 4.0–4.5 ml/min/g liver for 90 minutes. After
20 minutes, sulfasalazine (or the carrier DMSO only, 0.001%
v/v) was continuously infused for 70 minutes to reach a final
concentration of 100 mmol/l in the portal vein. After
30 minutes, the bile acid GCDCA (or the carrier DMSO only,
0.1% v/v) was infused for 60 minutes at a continuous rate to
reach a final concentration of 25 mmol/l or 12.5 mmol/l in the
portal vein. Hepatovenous efflux of lactate dehydrogenase
(LDH) and glutamate-pyruvate transaminase (GPT) as
indicators of liver cell damage were measured by use of
standard enzymatic tests.16 Bile flow was measured gravimet-
rically in prepared tubes.
Immunofluorescence microscopy
Activated caspase 3 and cytokeratin intermediate filament
alterations, typical of apoptotic cell death, were studied as
described previously.17 For quantification, caspase 3 positive
hepatocytes with concomitant cytokeratin intermediate fila-
ment breakdown were counted in 20 different high power
fields per sample and expressed as x-fold increase over
control.
Determination of bile acids
GCDCA concentrations in the hepatovenous effluate were
determined as described previously.18 Briefly, bile acids were
extracted with Bond-Elut C18 cartridges (Analytichem
International, San Diego, California, USA). Deconjugated
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bile acids were isolated by extraction on Lipidex 1000
(Packard Instruments, Groningen, the Netherlands) and
were then methylated and trimethylsilylated. Capillary gas
chromatography was performed using a Carlo Erba Fractovap
4160 analyser (Carlo Erba, Hofheim, Germany). Bile acid
derivates were separated on a silica capillary CP Sil 19 CB
column (Chrompack, Middelburg, the Netherlands). Eluted
bile acid derivates were detected by a flame ionisation
detector.
Statistics
Results from at least three independent experiments are
expressed as mean (SD). Differences between groups were
compared using an analysis of variance for repeated
measures and a post hoc Bonferroni test to compare for
multiple comparisons.
RESULTS
Does sulfasalazine or its metabolites modulate bile
acid induced apoptosis in vitro?
The bile acid transporting human hepatoma cell line HepG2-
Ntcp14 was used for the in vitro studies. GCDCA effectively
induced apoptosis in this cell line while parent non-bile acid
transporting HepG2 cells were not sensitive to GCDCA
induced apoptosis (fig 1A). Based on these results,
75 mmol/l of GCDCA was used for the remainder of the in
vitro studies.
A dose dependent reduction in GCDCA induced apoptosis
was observed when sulfasalazine was used in combination
with 75 mmol/l of GCDCA. After four hours, sulfasalazine
1000 mmol/l reduced GCDCA induced caspase 3/7 activity to
control levels; 100 mmol/l resulted in a 80 (12)% reduction
and 10 mmol/l in a 25 (7)% reduction in caspase 3/7 activity
(fig 1B). Sulfasalazine 1 mmol/l had no effect on GCDCA
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Figure 1 Sulfasalazine reduced bile acid induced apoptosis in a
hepatoma cell line. (A) HepG2-Ntcp and parent HepG2 cells were
treated with diluent or glycochenodeoxycholic acid (GCDCA) at the
indicated concentrations for four hours. The pancaspase inhibitor ZVAD-
FMK (20 mmol/l) was used to demonstrate the specificity of the assay.
Apoptosis was quantified by measuring caspase 3/7 activity and
expressed as a percentage over controls (set as 100%). (B) HepG2-Ntcp
cells were treated with GCDCA (75 mmol/l) in the presence or absence
of sulfasalazine (SSZ) at the indicated concentrations. Apoptosis was
quantified by measuring caspase 3/7 activity (*p,0.05; p,0.01 v
GCDCA). (C) HepG2-Ntcp cells were treated with GCDCA (75 mmol/l)
in the presence or absence of SSZ at the indicated concentrations.
Apoptosis was quantified by measuring caspase 9 activity (*p,0.05;
p,0.01 v GCDCA). Results are mean (SD) of six independent
experiments.
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Figure 2 5-Aminosalicylic acid and sulfapyridine did not affect bile
acid induced apoptosis. HepG2-Ntcp cells were treated with diluent or
glycochenodeoxycholic acid (GCDCA 75 mmol/l) in the presence or
absence of 5-aminosalicylic acid (5-ASA) (A) or sulfapyridine (SPD) (B)
at the indicated concentrations for four hours. Apoptosis was quantified
by measuring caspase 3/7 activity and expressed as a percentage over
controls (set at 100%). Results are mean (SD) of three independent
experiments.
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induced apoptosis. Because HepG2-Ntcp is a hepatoma cell
line, we also repeated this experiment using 18 hour cultured
primary mouse hepatocytes and confirmed the dose depen-
dent antiapoptotic effect of sulfasalazine on GCDCA induced
apoptosis which was nearly identical to that shown in fig 1B
(n = 3; data not shown).
Hepatocytes are considered to be type II cells in which the
mitochondrial pathway is essential to induce apoptosis.19
Therefore, the effects of sulfasalazine on GCDCA induced
caspase 9 activation were examined. In these experiments,
sulfasalazine reduced GCDCA induced caspase 9 activation in
a dose dependent manner similar to the reduction in the
effector caspases 3/7 shown above (fig 1C).
We next evaluated the effects of the two metabolites of
sulfasalazine, 5-ASA and sulfapyridine, in the same experi-
mental system. In contrast with sulfasalazine, neither 5-ASA
nor sulfapyridine had any effect on GCDCA induced
apoptosis, as measured by caspase 3/7 activity (fig 2A, 2B).
The combination of 5-ASA and sulfapyridine in the same
ratio as present in sulfasalazine also did not alter GCDCA
induced apoptosis (data not shown). These data indicate that
sulfasalazine, but not its metabolites, is a potent inhibitor of
GCDCA induced apoptosis in hepatocytes.
Is NFkB activity in HepG2-Ntcp cells induced by
sulfasalazine?
The effect of sulfasalazine on NFkB activation in HepG2-Ntcp
cells was examined by EMSA and luciferase reporter gene
assays. Sulfasalazine induced NFkB activity in a dose
dependent manner in HepG2-Ntcp cells after one hour of
incubation (fig 3A). NFkB activation by 100 and 1000 mmol/l
sulfasalazine was also shown by EMSA (fig 3A, inset). In
comparison, GCDCA 75 mmol/l did not significantly affect
NFkB activity. Thus sulfasalazine appears to be an inducer of
NFkB in hepatoma cells. To assess the potential role of
sulfasalazine induced NFkB activation on its beneficial effect
on GCDCA induced apoptosis, the NFkB inhibitor MG132
(carbobenzoxyl-leucinyl-leucynil-leucynal)20 was used for
additional experiments. At a concentration of 50 mmol/l,
MG132 reduced sulfasalazine induced NFkB activation to
control levels, as demonstrated by EMSA (fig 3B) and
reporter gene assays (not shown). However, the effect of
sulfasalazine on GCDCA induced caspase 3/7 activity was not
altered by MG132 (fig 3C), indicating that this mechanism is
not relevant for the beneficial effects of sulfasalazine on
GCDCA induced apoptosis.
Does sulfasalazine reduce GCDCA induced ROS
generation?
To determine a possible effect of sulfasalazine on GCDCA
induced ROS generation, HepG2-Ntcp cells were loaded with
the fluorescent dye carboxy-H2-DCFDA and then incubated
with GCDCA (75 mmol/l) in the absence or presence of
sulfasalazine. GCDCA significantly increased generation of
Figure 3 Sulfasalazine induced nuclear factor kB (NFkB) activity.
(A) Hep-G2-Ntcp cells were cotransfected with TK-Renilla-CMV and Luc-
NFkB (p106). Cells were stimulated with diluent (DMEM), sulfasalazine
(SSZ) at the indicated concentrations, or glycochenodeoxycholic acid
(GCDCA 75 mmol/l) for one hour. Cell lysates were prepared, and
firefly and Renilla luciferase assays were performed. To control for
transfection efficiency, the ratio of firefly to Renilla luciferase was
calculated. The resulting values are presented as arbitrary units. The inset
shows an electrophoretic mobility shift assay (EMSA) for NFkB after
stimulation of HepG2-Ntcp cells with 100 or 1000 mmol/l SSZ or
medium only (control) for one hour. Results are mean (SD) of three
independent experiments (*p,0.05; **p,0.01; ***p,0.001 v control).
(B) HepG2-Ntcp cells were preincubated for one hour with MG132
(carbobenzoxyl-leucinyl-leucynil-leucynal) at the indicated
concentrations and SSZ (1000 mmol/l) or diluent (as control) was added
for one hour. Nuclear extracts were prepared and EMSAs were
performed. (C) HepG2-Ntcp cells were incubated with GCDCA, SSZ, or
diluent (as control) in the absence or presence of the NFkB inhibitor
MG132 (50 mmol/l) for four hours. Apoptosis was quantified by
measuring caspase 3/7 activity and expressed as a percentage over
control (set as 100%). Results are mean (SD) of three independent
experiments.
Table 1 Sulfasalazine reduced glycochenodeoxycholic
acid (GCDCA) induced oxidative stress in HepG2-Ntcp
cells
Condition Fold ROS formation
Control 1
GCDCA 75 mmol/l 1.28 (0.05)*
Sulfasalazine 1000 mmol/l 0.97 (0.02)
GCDCA 75 mmol/l+sulfasalazine 1 mmol/l 1.28 (0.04)
GCDCA 75 mmol/l+sulfasalazine 10 mmol/l 1.24 (0.01)
GCDCA 75 mmol/l+sulfasalazine 100 mmol/l 1.09 (0.03)
GCDCA 75 mmol/l+sulfasalazine 1000 mmol/l 1.00 (0.03)
HepG2-Ntcp cells were loaded for four hours with the fluorescent dye
carboxy-H2-DCFDA (4 mmol/l) to detect generation of reactive oxygen
species (ROS). Then, cells were incubated with GCDCA in the absence or
presence of sulfasalazine for two hours.
Data represent the n-fold increase in carboxy-H2-DCFDA fluorescence
compared with controls (set at 1).
Results are the mean (SD) of 12 independent experiments.
*p,0.01 v control; p,0.05, p,0.01 v GCDCA.
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ROS by nearly 30% compared with controls after two hours.
A combination of GCDCA with sulfasalazine (1–1000 mmol/l)
led to a dose dependent reduction in ROS generation which
reached control levels using sulfasalazine 1000 mmol/l
(table 1). As the proapoptotic Bcl-2 proteins Bax and Bid
have also been shown to be important for the mitochondrial
damage during bile acid induced apoptosis,21 additional
immunoblot experiments were performed. However, expres-
sion and activation of both Bax and Bid were not modulated
by sulfasalazine (data not shown).
Is bile acid uptake inhibited by sulfasalazine?
We next evaluated if sulfasalazine influenced bile acid uptake
as another possible mechanism for its antiapoptotic proper-
ties. Bile acid uptake under control conditions was set as
100%. Sulfasalazine at a concentration of 1 mmol/l had no
effect and at 10 mmol/l tended to reduce bile acid uptake in
HepG2-Ntcp cells, but the difference did not reach signifi-
cance (fig 4A). However, using 100 mmol/l sulfasalazine, bile
acid uptake was reduced to 71 (12)% compared with controls
and to 23 (7)% at 1000 mmol/l, both significantly differences.
In contrast, 5-ASA and sulfapyridine did not affect bile acid
uptake (fig 4A).
To determine the mechanism of sulfasalazine induced
reduction of bile acid uptake, the kinetics of bile acid uptake
in the absence or presence of sulfasalazine were evaluated.
The Km under control conditions was 42 mmol/l and
increased to 99 mmol/l (at 10 mmol/l sulfasalazine) and to
Figure 5 Sulfasalazine reduced staurosporine and tumour necrosis
factor a/actinomycin D induced apoptosis. (A) Subconfluent HepG2-
Ntcp cells were treated with diluent or staurosporine (STSP) in the
absence or presence of sulfasalazine (SSZ) or the pancaspase inhibitor
ZVAD-FMK at the indicated concentrations for four hours. Equivalent
amounts of proteins were immunoblotted with antibodies against
cleaved (Cl) caspase 3 or cleaved caspase 9. Membranes were then
stripped and reprobed with an anti-b-actin antibody to ensure equal
loading in an identical procedure. Representative blots from three
independent experiments are shown. (B) In addition, densitometry of
cleaved caspase 3 and b-actin was performed and expressed as the
ratio cleaved caspase 3/b-actin. Results are mean (SD) of three
independent experiments (*p,0.05, p,0.01 v STSP). (C) HepG2-
Ntcp cells were treated with tumour necrosis factor a (TNF-a 28 ng/ml)
in combination with actinomycin D (ActD 0.2 mg/ml) in the presence or
absence of SSZ at the indicated concentrations. Apoptosis was
quantified by measuring caspase 3/7 activity. Results are mean (SD) of
three independent experiments (*p,0.05 v TNF-a/ActD).
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Figure 4 Sulfasalazine competitively inhibited bile acid uptake. (A)
HepG2-Ntcp cells were incubated with[3H]-taurocholic acid (1 mCi/ml)
in the absence or presence of sulfasalazine (SSZ), 5-aminosalicylic acid
(5-ASA), or sulfapyridine (SPD) at the indicated concentrations for
10 minutes. Cells were then washed, lysed, and radioactivity measured
in an automated counter. Results are mean (SD) of six independent
experiments and are expressed as a percentage of controls (*p,0.05;
**p,0.01 v control). (B) HepG2-Ntcp cells were incubated with[3H]-
taurocholic acid (1 mCi/ml) at different concentrations (0–100 mmol/l)
in the absence or presence of SSZ (10 and 100 mmol/l). The
corresponding Km and Vmax values were calculated after measuring
intracellular radioactivity and plotted as a Lineweaver-Burk graph.
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263 mmol/l (at 100 mmol/l sulfasalazine). Vmax values were
nearly unchanged (0.24 (0.03) nmol/min/mg protein) under
all experimental conditions. Inhibition was thus competitive,
as also shown in the Lineweaver-Burk plot (fig 4B).
Does sulfasalazine also inhibit apoptosis that is not
induced by bile acids?
Staurosporine, a non-specific kinase inhibitor, induces
apoptosis through disruption of mitochondrial function.22
At a concentration of 5 mmol/l, staurosporine readily induced
cleavage of caspase 9 and caspase 3 in HepG2-Ntcp cells,
which was inhibited by the pancaspase inhibitor ZVAD-FMK
(fig 5A). Treatment with staurosporine and sulfasalazine (1–
1000 mmol/l) resulted in a dose dependent reduction in both
caspase 9 and caspase 3 cleavage. Densitometric analysis of
the cleaved caspase 3 immunoblots (normalised to b-actin)
revealed that staurosporine induced caspase 3 cleavage was
significantly reduced when 100 or 1000 mmol/l sulfasalazine
were administered (fig 5B). Similar results were obtained for
cleaved caspase 9 (data not shown). Sulfasalazine also dose
dependently reduced caspase 3/7 activity when TNF-a and
actinomycin D were used as an apoptotic stimulus that
requires Fas signalling (fig 5C). These results indicate that
inhibition of intracellular apoptosis signalling might be more
important for the antiapoptotic effects of sulfasalazine than
the observed reduction in bile acid uptake.
Does sulfasalazine ameliorate GCDCA induced liver
damage in the intact organ?
Livers of Sprague-Dawley rats were perfused with sulfasala-
zine (100 mmol/l) or the carrier DMSO only (0.1% v/v) for
70 minutes beginning at 20 minutes. GCDCA (25 mmol/l)
was infused for 60 minutes beginning at 30 minutes. We
have recently demonstrated that GCDCA (25 mmol/l) induces
widespread hepatocyte apoptosis and liver damage in
perfused rat livers.23 In contrast, GCDCA induced apoptosis
and liver injury were significantly reduced by simultaneous
perfusion with 100 mmol/l sulfasalazine: LDH and GPT
activities were reduced by 82% and 87%, respectively,
compared with GCDCA perfused livers (fig 6A).
Correspondingly, apoptotic hepatocytes were only observed
occasionally compared with the extensive hepatocyte apoptosis
Figure 6 Sulfasalazine reduced bile
acid induced liver injury and apoptosis
in perfused rat livers. Rat livers were
perfused with 25 mmol/l glycocheno-
deoxycholic acid (GCDCA) or the
carrier dimethyl sulfoxide only, in the
absence or presence of 100 mmol/l
sulfasalazine (SSZ) for 60 minutes.
(A) After 55 minutes of bile acid
administration, lactate dehydrogenase
(LDH) and glutamate-pyruvate
transaminase (GPT) activities in the
hepatovenous effluate were determined
photometrically. Results are mean (SD)
of six independent experiments.
(B) Hepatocyte apoptosis was
determined by immunohistochemistry of
activated cleaved (Cl) caspase 3 and
double immunofluorescence labelling
for activated caspase 3 and cytokeratin
(CK) 18. After 60 minutes, double
immunofluorescence labelling for CK
18 (green) and activated caspase 3 (red
and yellow due to colocalisation with
CK 18) in GCDCA treated livers
revealed massive hepatocellular
activation of caspase 3 in cells with CK
intermediate filament breakdown and
granular cytoplasmic condensation. In
contrast, immunoreaction for activated
caspase 3 was similar to controls in
livers perfused with GCDCA and SSZ
(magnification6400). Representative
images from six independent
experiments are shown.
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(.100-fold compared with controls) observed after treatment
with GCDCA alone (fig 6B). Sulfasalazine by itself did not cause
liver damage or hepatocyte apoptosis. Thus sulfasalazine
distinctly reduces GCDCA induced apoptosis and liver damage
in the intact liver also.
Is GCDCA induced cholestasis reversed by
sulfasalazine?
Bile flow was 1.31 (0.31) ml/min/g of liver (n = 6) after
20 minutes before bile acids or their carrier DMSO (0.1% v/v)
were infused, indicating an adequate secretory capacity of the
livers. GCDCA (25 mmol/l) reduced bile flow to 17% of
controls (p,0.01 v control). Sulfasalazine alone (100 mmol/l)
also reduced bile flow to 62% of controls (p,0.05 v control).
In contrast, sulfasalazine markedly increased bile flow in
GCDCA treated livers to 79% of controls (p,0.05 v GCDCA)
(fig 7). Thus sulfasalazine partially reversed GCDCA induced
cholestasis in the intact liver.
Does sulfasalazine reduce bile acid uptake in the
intact organ?
We investigated the possible role of sulfasalazine induced
reduction of bile acid uptake as a major mechanism for its
protective effect on GCDCA induced liver damage in the
perfused liver. Bile acid uptake was calculated by subtracting
GCDCA concentration in the hepatovenous effluate from the
concentration in the portal vein because this difference likely
reflects uptake of bile acids into the liver. Similar to the
results observed in HepG2-Ntcp cells, GCDCA uptake was
reduced by 45 (5)% after 45 minutes of perfusion with
sulfasalazine (n = 6), suggesting inhibition of bile acid
uptake as a possible mechanism for the protective effect of
sulfasalazine (fig 8A). Based on this experiment, we next
evaluated if half the dose of GCDCA (12.5 mmol/l)—which is
presumably taken up by the liver during concomitant
administration of sulfasalazine and 25 mmol/l GCDCA—still
causes liver damage and hepatocyte apoptosis. If inhibition of
uptake is a major mechanism of protection, liver damage
should not occur using 12.5 mmol/l GCDCA. However, when
12.5 mmol/l GCDCA was used, marked hepatocyte apoptosis
(fig 8B) and liver injury (GPT 40.7 (9.5) mU/min/g) still
occurred (fig 8C). A combination of 12.5 mmol/l GCDCA and
100 mmol/l sulfasalazine again significantly reduced liver
damage and hepatocyte apoptosis (data not shown). Thus
inhibition of bile acid uptake appears to play only a minor role
in the protective effects of sulfasalazine in the intact liver.
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Figure 7 Sulfasalazine partially reversed glycochenodeoxycholic acid
(GCDCA) induced cholestasis. Dimethyl sulfoxide (0.1% v/v), GCDCA,
sulfasalazine (SSZ), and GCDCA in combination with SSZ were
administered for 60 minutes (GCDCA) and 70 minutes (SSZ). GCDCA
significantly reduced bile flow (p,0.01 v control). While SSZ alone
decreased bile flow, SSZ significantly increased bile flow in GCDCA
treated livers (*p,0.05, **p,0.01 v control; p,0.05 v GCDCA).
Results are expressed as mean (SD) of six experiments.
Figure 8 Reduced bile acid uptake is not sufficient to explain the effects
of sulfasalazine in the intact liver. Rat livers were perfused with
glycochenodeoxycholic acid (GCDCA 12.5 or 25 mmol/l) or the carrier
dimethyl sulfoxide only, in the absence or presence of 100 mmol/l
sulfasalazine (SSZ) for 60 minutes. (A) After 15 minutes of bile acid
administration, chenodeoxycholic acid concentrations were determined
in the hepatovenous effluate. The difference between portal vein
concentration (concentration in the perfusate) and hepatic vein
concentration (concentration in the effluate) as an indirect measure of
bile acid uptake into the liver is mapped on the y axis. GCDCA at both
concentrations was almost completely taken up into the liver because it
could only be detected in trace amounts in the hepatovenous effluate. In
contrast, 11 (1) mmol/l of chenodeoxycholic acid were detected in the
hepatovenous effluate when GCDCA (25 mmol/l) and SSZ (100 mmol/l)
were administered, indicating that nearly 50% of GCDCA was not taken
up. Bile acid uptake into the liver was almost identical when GCDCA was
administered at 12.5 mmol/l or was coadministered with SSZ
(100 mmol/l) at 25 mmol/l. (B) Hepatocyte apoptosis was determined by
immunohistochemistry of activated caspase 3 and cytokeratin (CK) 18
after 60 minutes of bile acid administration (magnification 6400).
Hepatocyte apoptosis was markedly more pronounced with GCDCA
12.5 mmol/l compared with GCDCA 25 mmol/l in combination with
100 mmol/l SSZ, although bile acid uptake into the liver was similar
under both conditions. Representative images from six independent
experiments are shown. (C) After 55 minutes of bile acid administration,
glutamate-pyruvate transaminase (GPT) activities in the hepatovenous
effluate were determined photometrically. Comparable to (B), GPT efflux
as a marker of liver damage was significantly increased with GCDCA
12.5 mmol/l compared with GCDCA 25 mmol/l in combination with
100 mmol/l SSZ (**p,0.01). Results in (A) and (C) are mean (SD) of six
independent experiments.
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DISCUSSION
The principle findings of this study indicate that sulfasalazine
is a potent inhibitor of bile acid mediated hepatocyte
apoptosis in vitro and in the intact liver. In addition,
sulfasalazine ameliorates GCDCA induced cholestasis in
perfused rat livers. These results suggest that sulfasalazine
may be of potential benefit in the treatment of cholestatic
liver diseases by reducing liver injury and cholestasis.
At present, there are no data concerning the effects of
sulfasalazine on apoptosis in hepatocytes. In T lymphocytes,
sulfasalazine has been shown to induce apoptosis by caspase
independent mechanisms.24 In a recent study, sulfasalazine
promoted hepatic stellate cell apoptosis in vitro and in vivo.25
In human glioma cells and colon carcinoma cell lines,
sulfasalazine inhibited Fas mediated apoptosis but simulta-
neously sensitised the cells to TRAIL mediated apoptosis.26
However, apoptosis could not be induced by sulfasalazine in
SW620 colon carcinoma cells or primary human synovio-
cytes.24 Thus there appears to be a cell type specific sensitivity
to sulfasalazine. In the present study, sulfasalazine inhibited
Fas dependent apoptosis because GCDCA as well as TNF-a/
actinomycin D induced apoptosis are considered Fas depen-
dent.4 27 Sulfasalazine also inhibited staurosporine induced
apoptosis, suggesting that its protective effect is not limited
to reduced formation of the death inducing signalling
complex.
In contrast with studies in colon epithelial cells, hepatic
stellate cells, and T lymphocytes,13 25 28 sulfasalazine induced
NFkB activity in our model. However, this NFkB activation
does not appear to be responsible for the observed beneficial
effects of sulfasalazine because GCDCA induced apoptosis
was unchanged when sulfasalazine was administered
together with the NFkB inhibitor MG132. Interestingly,
sulfasalazine modulated apoptosis in a NFkB independent
manner in human glioma cells although sulfasalazine also
significantly altered NFkB activity in this model.26 However,
sulfasalazine appears to have a protective effect on mito-
chondria, as suggested by its capacity to reduce GCDCA
induced ROS generation and caspase 9 activation, and by its
reduction of staurosporine induced cytotoxicity, a model of
cell death known to be mediated by mitochondrial dysfunc-
tion.29 Thus inhibition of the mitochondrial pathway might
be partly responsible for the protective effect of sulfasalazine
in our model. Interestingly, sulfasalazine has been described
as a ROS scavenger in the past.30 31
Sulfasalazine reduced bile acid uptake in hepatocytes at
higher concentrations. This reduction is due to competitive
inhibition of the transfected bile acid transporter Ntcp. As
uptake of GCDCA is necessary to induce apoptosis, it could be
speculated that this is the major mechanism of action in our
model. However, at a concentration of 100 mmol/l sulfasala-
zine, 70% of bile acids were still taken up by HepG2-Ntcp cells
and 50 mmol/l GCDCA (equivalent to 75 mmol/l GCDCA in
combination with 100 mmol/l sulfasalazine) readily induces
hepatocyte apoptosis. In addition, sulfasalazine also inhibited
staurosporine induced apoptosis in HepG2-Ntcp cells. Thus a
direct effect on apoptosis signalling appears more important
than the reduction in bile acid uptake because staurosporine
does not require active transport into cells.22 This conclusion
is further supported by perfusion studies. Sulfasalazine
inhibited GCDCA induced apoptosis almost to control levels
although bile acid uptake was only reduced by approximately
50%. In addition, when GCDCA was used at half the
concentration (12.5 v 25 mmol/l), which is presumably still
taken up by hepatocytes during sulfasalazine administration,
significantly more liver damage and hepatocyte apoptosis
occurred compared with the combination of sulfasalazine
and GCDCA 25 mmol/l. This strongly suggests that the major
mechanism of action of sulfasalazine on reduction of GCDCA
induced liver damage is inhibition of apoptosis signalling.
Reduction of bile acid uptake appears to be only a minor
contributing mechanism.
Sulfasalazine partly reversed GCDCA induced impairment
of bile flow in our model. How can this observation be
explained? GCDCA is a toxic bile acid that significantly
decreases bile flow, in part due to hepatocyte injury.
Sulfasalazine protects the liver against GCDCA induced
injury thereby restoring the capacity of the liver to generate
bile. In addition, GCDCA might contribute to bile acid
dependent bile flow when its cytotoxic effects are inhibited
by sulfasalazine.32
The two metabolites of sulfasalazine, 5-ASA and sulfapyr-
idine, had no effect on GCDCA induced apoptosis. Similar
observations have also been made in other models. In colon
epithelial cells, sulfasalazine but not its metabolites sup-
pressed NFkB activity12 13 and likewise, in T lymphocytes,
only sulfasalazine induced apoptosis.28 Thus only the intact
molecule seems to modulate intracellular signalling. This
observation appears to be of clinical significance because only
sulfasalazine, and not 5-ASA, has beneficial effects in
rheumatoid arthritis as a disease modifying agent.33
The protective effects of sulfasalazine observed in the
present study were most pronounced at concentrations of 100
and 1000 mmol/l. Early studies have shown that peak serum
levels of approximately 100 mmol/l sulfasalazine are reached
in the serum of patients after oral administration.34 The
concentration of sulfasalazine in the portal vein, which is
crucial for the concentration reached in hepatocytes, is
presumably even higher, because sulfasalazine undergoes
enterohepatic circulation.35 Thus our results may have
therapeutic implications for patients with chronic cholestasis.
In summary, the data presented in the current study
suggest that bile acid mediated apoptosis can be effectively
inhibited by sulfasalazine at concentrations that are reached
during therapeutic application of this drug in patients.
Together with recent findings that sulfasalazine reduces
hepatic fibrosis by promoting hepatic stellate cell apoptosis,25
our results have potential implications for reducing liver
injury during cholestasis. This novel therapeutic strategy
deserves further study, for example in patients with primary
sclerosing cholangitis and ulcerative colitis which are
concurrently treated with sulfasalazine.
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